Which unit still has this performance, I also want to apply

(0) 讚！ | 大力冰可

Performance is excellent, with an impact factor of 10,000 and two articles per year, making an annual salary of one million

(0) 讚！ | 魔都小柔

Same as always, urged again

(0) 讚！ | 九阳莺韵

How are things going now?

(0) 讚！ | 魔都吉星

It has been so long... It's beyond words

(0) 讚！ | 魔都小柔

Submitted for review, but unable to secure enough reviewers

(0) 讚！ | 九阳莺韵

Checked?

(0) 讚！ | 魔都小柔

Not bad, what's up with you guys, can't find these two articles or don't know English letters?

(0) 讚！ | Debby Bell

I don't want to offer a high reward, that's all

(0) 讚！ | 上清寒灵

Review speed: 12.0 | Submission hit rate: 25.0
Emphasized research direction: circRNA
Sharing experience: Submitted in March 2022, still not reviewed! Just close down if you can't find reviewers

(0) 讚！ | 九阳莺韵

Research focus: Tumor Experience Sharing: Everyone, recently submitted a review to Molecular Cancer, received major revisions after two months of initial review, and after revising, it has been in the second review for a month and now shows "Reviewer reports received / Ready for editor's decision." It has been 3 days and there has been no change. How long does it usually take for a result in this kind of status? Could it be delayed because Christmas is approaching and the editors are on vacation?

(0) 讚！ | 安青mio

Seek advice from all seniors, my recent review article was submitted to Molecular Cancer, after the first review, it was given a major revision two months later, and after the second review, it shows "Reviewer reports received / Ready for editor's decision" for one month now. It has been 3 days since then, and there has been no further news. How long does it generally take to receive the results after the second review? Is it because of the approaching Christmas that the editor's decision is a bit slow?

(0) 讚！ | 安青mio

Sichuan University, Sun Yat-sen University, and Central South University have been publishing. Last year, Peking University, First Hospital, Fudan University, and Peking Union Medical College have all published this journal. Aren't these all prestigious universities?

(0) 讚！ | 深渊兰芳

Is this considered as escalating a scam? This is too much

(0) 讚！ | Jeff Morgan

molecular cancer, molecular cancer research, cancer research names all seem similar

(0) 讚！ | 小海宾吖

Please translate the following paragraph into English and Japanese, and title it with ":" and ":"

(0) 讚！ | Miriam Franklin

Review Speed: 6.0 | Submission Success Rate: 50.0
Research Focus: Tumor microenvironment
Experience Sharing: Assistant Professor Lorenzo Galluzzi from Cornell University just published a review on NK cells today. He was born in 1980 and has published 473 SCI papers so far, with 197 of them scoring over 10 points

(0) 讚！ | 深渊兰芳

What is the current status of the submission? How many stages are there in total?

(0) 讚！ | 截手爱敏

Significantly below the standards of the magazine, there is no need to enter the review process

(0) 讚！ | 坠星倩影

This magazine is so good, but it's also slow. The BMC series is very slow

(0) 讚！ | 坠星倩影

Hmm... After receiving a rejection letter from the editor, he recommended several other BMC journals, and it felt like the editor responded to emails quickly during the exchange

(0) 讚！ | 雾都颖昕

Almost there with the oncogene article. Another article on Cell Reports is no problem

(0) 讚！ | 深渊兰芳

I graduated from Shandong Medical University with a bachelor's degree and from Peking University with a master's degree. Later, I went to the United States to practice medicine

(0) 讚！ | 深渊兰芳

I have heard of more than one case of molecular Cancer being published. Of course, they also have other articles in journals like oncogene, cancer research, and so on. It also depends on how well-written their papers are

(0) 讚！ | 深渊兰芳

Review speed: 3.0 | Submission success rate: 50.0 
Research focus: Immunology; 
Tumor experience sharing: Michael Wang, a blood tumor expert from the US Anderson, published today that TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Quite good. Hope Molecular Cancer publishes more articles like this, and fewer articles on water filling and circRNA tricks

(0) 讚！ | 深渊兰芳